ASCO 2022 Annual Meeting

  • June 3, 2022 - June 7, 2022
  • Chicago, IL

Biomica is delighted to participate at the 2022 ASCO Annual Meeting.

Biomica’s abstract, entitled “A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors,” was selected for a poster and presentation session at the conference.

This poster has also been selected for the 2022 GRASP Advocate Choice Award. GRASP, which stands for Guiding Researchers and Advocates to Scientific Partnerships, and is a patient-led organization that brings together patients, clinicians, and researchers to exchange ideas and learn from each other to accelerate scientific breakthroughs.

For more details and registration: www.ASCO.org

Back to all News

Highlighted News About Biomica

May 23, 2024

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]

Read More